According to AVACEN Medical, Executive Chairman, Thomas G. Muehlbauer: “I’m very proud our team was able to accomplish this while navigating inflationary pressures, rising interest costs, and hiring challenges from 2020 through 2023. Sales of our innovative medical devices normally require a personal demonstration, which of course was severely impeded during 2021 COVID pandemic. With over 25 million safe treatments, AVACEN devices are a proven alternative for treating pain and aiding wellness.”
Muehlbauer described AVACEN devices as: “the only known FDA-cleared, Class II, OTC medical devices on the market today able to provide noninvasive, rapid whole-body treatment, using a single point of contact. It is the ideal drug-free and safe alternative for relief of pain associated with multiple conditions such as arthritis.”
Read the Full Press Release >>